Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended‐Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials

Upadacitinib is a Janus kinase 1 inhibitor under development for the treatment of several inflammatory disorders including rheumatoid arthritis (RA). Upadacitinib was administered in the phase 2 RA trials primarily as twice‐daily regimens of an immediate‐release (IR) formulation. The upadacitinib ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Mohamed‐Eslam F., Zeng, Jiewei, Marroum, Patrick J., Song, In‐Ho, Othman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585649/
https://www.ncbi.nlm.nih.gov/pubmed/29688617
http://dx.doi.org/10.1002/cpdd.462

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585649/
https://www.ncbi.nlm.nih.gov/pubmed/29688617
http://dx.doi.org/10.1002/cpdd.462

Ejemplares similares